To provide an integrated view of endoplasmic reticulum (ER) function in protein export, we have described the interdependence of protein folding energetics and the adaptable biology of cellular protein folding and transport through the exocytic pathway. A simplified treatment of the protein homeostasis network and a formalism for how this network of competing pathways interprets protein folding kinetics and thermodynamics provides a framework for understanding cellular protein trafficking. We illustrate how folding and misfolding energetics, in concert with the adjustable biological capacities of the folding, degradation, and export pathways, collectively dictate an adaptable standard for protein export from the ER. A model of folding for export (FoldEx) establishes that no single feature dictates folding and transport efficiency. Instead, a network view provides insight into the basis for cellular diversity, disease origins, and protein homeostasis, and predicts strategies for restoring protein homeostasis in protein-misfolding diseases.
INTRODUCTION
One third of the eukaryotic proteome is folded by the endoplasmic reticulum (ER) for delivery to downstream compartments that form the diverse membrane architectures defining the exocytic and endocytic pathways of eukaryotic cells. An understanding of the principles regulating protein folding and export from the ER versus degradation is important, because defects in partitioning are the foundation for many protein-misfolding diseases (Aridor, 2007; Cohen and Kelly, 2003) . Mutations in cargo proteins can lead to loss-of-function diseases because of the failure of those proteins to be selected by the coatomer complex II (COPII) export machinery directing ER export , resulting in their removal by the ER-associated degradation (ERAD) pathway (Brodsky, 2007) . Examples include the DF508 cystic fibrosis transmembrane conductance regulator (CFTR) protein responsible for cystic fibrosis (Guggino and Stanton, 2006) , variants of a 1 -antitrypsin (a1AT) leading to childhood emphysema (Perlmutter, 2006) , and N370S b-glucocerebrosidase responsible for the majority of Gaucher disease cases (Sawkar et al., 2006) . Other mutations, such as the Z variant of a1AT, can result in misfolded protein accumulating in the ER, triggering an unfolded protein response and apoptosis, with apoptosis being the outcome when protein homeostasis cannot be reestablished (Perlmutter, 2006) . In contrast, the gain-of-toxicity category of protein-misfolding diseases, including the amyloidoses, are believed to result from aggregation-prone proteins being efficiently exported from the ER, after which they misassemble into pathogenic structures in the extracellular space (Cohen and Kelly, 2003; Page et al., 2005; Sekijima et al., 2005) .
The ER-assisted folding (ERAF) pathways (Sekijima et al., 2005) , which are essential for protein export, use many chaperones and folding catalysts to direct the folding of both lumenal and cytosolic domains (Shimizu and Hendershot, 2007) . The folding of ER lumenal domains is aided by abundant chaperones including BiP and the Hsp90-related GRP94 components, as well as the calnexin/calreticulin cycle facilitating N-linked glycoprotein folding (Helenius and Aebi, 2004) . Folding catalysts include protein disulfide isomerases (PDI) and cis/trans peptidyl-prolyl isomerases. In addition to assisting the folding of soluble exported cargo proteins, these ER lumenal chaperones and folding enzymes collaborate with cytosolic chaperones to coordinate the folding of transmembrane proteins having cytosolic domains. The cytosolic chaperones include Hsc-Hsp40/70 and Hsp90 members (Bukau et al., 2006; Queitsch et al., 2002; Young et al., 2004) . Metabolites and other small molecules that bind to native proteins can also stabilize them in either the ER or the cytosol, enabling export (Sawkar et al., 2006; Sekijima et al., 2005) . The ERAF pathways that link protein cargo to the COPII export machinery are in competition with the ERAD machinery directing dislocation from the ER, targeting the protein to the cytosolic proteasome for degradation. The ERAD, ERAF, and COPII export pathways comprise a versatile and integrated biological network that directs ER function, although a rigorous quantitative assessment of the relative contributions of these pathways in (patho)physiology remains to be established.
Although there is evidence that protein export efficiency decreases as thermodynamic stability decreases (Kowalski et al., 1998; Kumita et al., 2006; Sekijima et al., 2005) , this correlation is a special case requiring the folding kinetics to be fast (Sekijima et al., 2005) . We recently utilized transthyretin (TTR) variants with a wide range of folding kinetics and thermodynamics to correlate the level of protein cargo export with folding energetics. Thermodynamic and kinetic parameters were integrated to generate a folding stability score (Sekijima et al., 2005) , providing a means to appreciate their relative contribution to protein export through the secretory pathway.
To render the insight gained with TTR more useful and even predictive, we present a quantitative model of ER function in folding for export (referred to as FoldEx) herein. FoldEx combines protein folding energetics and a simplified Michaelis-Menten treatment of the protein homeostasis network comprising the ERAF, ERAD, and export pathways, rationalizing a large body of existing experimental results and enabling predictions to be made where experimental data are lacking. By treating pathways as discrete entities analogous to enzymes, we can recapitulate the essence of the folding/export/degradation network. The energetics of the protein of interest is evaluated by the components of the ERAF, ERAD, and export machineries by binding to unfolded, misfolded, and folded protein states to dictate export efficiency. Different cells have distinct distributions and concentrations of ERAD, ERAF, and export components and will therefore have different export capacities and efficiencies (Sekijima et al., 2005) . For example, choroid plexus cells secrete the same relatively unstable transthyretin variants that liver cells largely degrade (Sekijima et al., 2005) . FoldEx enables an integration of protein energetics with the concentration and distribution of the ERAD, ERAF, and export pathway components which together dictate cellular protein export efficiency. FoldEx uses parameters defining the physical chemistry of protein folding and the biology of folding pathways, thus providing a robust framework to rationalize the operation of the exocytic pathway in the context of eukaryotic cellular diversity.
RESULTS

Energetic Principles of ER Export
The populations of the unfolded (U), misfolded (M), and folded (F) conformational ensembles or states are dictated by their energies, as depicted by an energy landscape model wherein each point in the x-y plane represents a unique conformation with an energy defined by the z coordinate ( Figure 1A ) (Oliveberg and Wolynes, 2005) . The influence of a destabilizing mutation on protein export is partly attributed to altered energies and populations of specific conformational ensembles. The unfolded wild-type (U) and mutant (U 0 ) conformational ensembles ( Figures 1A and 1B , respectively) of a given hypothetical protein are assumed to lack extensive specific interresidue contacts and therefore have nearly equal energies. In contrast, the differences in energy between wild-type (WT) and mutant folded ensembles (F and F 0 ) are typically larger, because specific interresidue contacts are locally disrupted by the mutation. The misfolded state is defined as a nonnative, conformationally heterogeneous ensemble of states largely lacking native contacts, which cannot efficiently revert to U and F. Thus, the influence of a mutation on the M state is generally modest due to its conformational heterogeneity. As illustrated in Figure 1B , mutations generally destabilize the F ensemble, leading to higher populations of U and M.
These population changes provide a mechanism for regulating export from the ER. The increased populations of U 0 and M 0 in the mutant protein facilitate increased interactions with components of the ERAD and ERAF pathways, increasing protein flow to degradation and recovery, respectively. Furthermore, the decreased population of F 0 reduces its interaction with the export machinery, thereby decreasing protein export from the ER.
The heights of the energy barriers separating the U, M, and F (U 0 , M 0 , and F 0 ) ensembles determine the rates at which these states interconvert. When equilibration between these ensembles is slow relative to the export rate because of high energy barriers, kinetics have a strong influence on the steady-state populations of U, M, and F and therefore on export efficiency along with the influence of thermodynamics.
Experimental Foundation for Understanding ER Export
The reasonable assumption that ER export is regulated through bimolecular interactions between U, M, and F and components of the export, ERAF, and ERAD machineries allows us to evaluate the influence of folding kinetics and thermodynamics on export efficiency. The assumption that the F ensemble engages the export machinery can be qualitatively tested by plotting the measured thermodynamic stability versus the measured cellular export efficiency for bovine pancreatic trypsin inhibitor (BPTI) from yeast (Kowalski et al., 1998 ) and a monomeric construct of transthyretin (M-TTR) from baby hamster kidney (BHK) cells (Sekijima et al., 2005 ) (fast-folding proteins). The folding equilibrium constant (referred to as K U/F ) determines the concentration of protein in the F and U ensembles at equilibrium. The folding free energy (DG U/F ) and folding equilibrium constant (K U/F ) are related by the equation DG U/F = -RT lnK U/F , indicating that the folding free energy can be used to define a folding equilibrium constant for each exported protein (Fersht, 1999) . Figure 2 shows that export efficiency is close to 0 for very unstable proteins, then increases as stability increases until an upper limit is reached; that is, export efficiency has a sigmoidal dependence on K U/F (when K U/F is plotted on a log scale). Likewise, the dependence of the population of the F ensemble on K U/F is similar, qualitatively supporting the hypothesis that export efficiency is related to the population of the F ensemble. Furthermore, the data in Figure 2 enable us to test another hypothesis: that no matter how complicated the export pathway actually is , it can be treated as though it were an enzyme. Like an enzyme, we propose that the export pathway recognizes a protein fold, its substrate, with a given binding constant and then exports it with a given kinetic constant. The hypothesis that the ERAF and ERAD pathways can be similarly simplified, without losing insight into the competing ERAD, ERAF, and export networks, can be directly tested.
The FoldEx Model of Protein Export from the ER A model of folding for export (FoldEx), based on the interplay between protein kinetics and thermodynamics and a Michaelis-Menten treatment of the adaptable biology of the ERAD, ERAF, and export machineries (thinking of each ''pathway'' as an ''enzyme'') is illustrated by Figure 3 . Exported proteins are cotranslationally inserted into the ER through the Sec61 translocon, denoted with a T (pathway 1). In the absence of chaperones, the unfolded conformational ensemble (U) would simply be released into the ER when protein translocation is complete (pathway 2). However, the nascent, unfolded polypeptide is generally bound by a chaperone(s) from the ERAF pathway (pathway 3) as it is being inserted into the ER (TUC 1 ). These chaperones typically have a low-affinity (ADP-bound) state and a high-affinity (ATP-bound) state. The nascent protein is initially bound by chaperones in the high-affinity state, after which the chaperone-protein complex (C 1 U) is released into the ER lumen (pathway 4). When the chaperone converts from the high-affinity to the low-affinity state in response to ATP hydrolysis (C 2 U) (pathway 5), it liberates the protein (pathway 6), affording it the opportunity 
Figure 2. Dependence of Protein Export Efficiency on Protein Folding Thermodynamics
A plot of export efficiency versus thermodynamic stability (K U/F ) for (A) bovine pancreatic trypsin inhibitor (BPTI) in yeast (Kowalski et al., 1998) and (B) a monomeric construct of transthyretin (M-TTR) from baby hamster kidney (BHK) cells (Sekijima et al., 2005 (Figure 3 ) to the data.
to fold. The released chaperone will switch back to its high-affinity state through ATP binding (not shown). If the protein fails to fold, the unfolded conformational ensemble can rebind to a chaperone and go through another ERAF cycle (pathway 7) as defined by the green box. Alternatively, it can reversibly adopt a properly folded ensemble of conformations (F) (pathway 8), which can be bound by the ''export machinery'' (E) and exported (pathways 9 and 10; blue box). If the protein fails to complete folding, U can engage the ERAD pathway (11 and 12; red box); that is, it can be recognized by the ''retrotranslocation machinery'' (R) and sent to the cytosol to be degraded by the proteasome (Brodsky, 2007) . Although it is generally believed that the U ensemble is only recognized by the ERAD pathway after multiple unsuccessful attempts at folding, the role of chaperones in recruiting substrates to ERAD (Brodsky, 2007) and the cotranslocational degradation of certain ER cargo proteins (Oyadomari et al., 2006) suggest that this is not the case. Moreover, the FoldEx model suggests that the fact that U can be recognized by ERAD does not necessarily result in a significant amount of ERAD unless there is a folding energetic defect (see below). Finally, the unfolded protein can misfold (pathway 13), thus populating the M state. In the first iteration of this model, we assume that misfolded proteins can only return to U with the assistance of chaperones (pathway 14; green box) because misfolded states including amorphous aggregates typically have high unfolding barriers. Misfolded proteins can also be recognized by the retrotranslocation machinery and be degraded by ERAD (pathways 15 and 16; red box).
Using FoldEx to Gain Insight into the Link between Export Efficiency and Energetics
To discern whether ER function in protein export is accurately described using FoldEx, we examined the influence of model parameters on ERAF, ERAD, and export capacity ( Figure 3 ). These parameters can be systematically varied to predict their role in export efficiency, which we define as the ratio of the export rate to the synthesis rate at steady state. To calculate the export efficiency, we assigned rate constants that describe each bimolecular interaction and folding reaction ( Figure 3 ). In addition, various concentrations of the export machinery ([E] tot ), retrotranslocation machinery ([R] tot ), and chaperones ([C] tot ) were explored. Each of the above machineries consists of many components. For example, in export, the F ensemble is selected through soluble or transmembrane adaptor complexes that are recruited to ER exit sites and into COPII-coated vesicles that bud and traffic the protein cargo to downstream compartments . In this hypothesis, the export machinery can be thought of as the enzyme, ensemble F as the substrate, and the export machinery-folded protein complex (EF) as the enzymesubstrate complex. Thus, k cat for the export machinery is k EF/E (i.e., the turnover rate for the enzyme-substrate complex), V max is k EF/E $[E] tot (i.e., the maximum rate of product formation at a given enzyme concentration), and K M is (k EF/E+F + k EF/E )/k E+F/EF (i.e., the concentration of substrate at which product formation is 1 ⁄ 2 V max ). As a second example, there is a large body of evidence that ERAD consists of many ER components that likely recognize U and M and deliver these conformational ensembles to the retrotranslocon for retrotranslocation and degradation (Brodsky, 2007) . As with export, we have assumed that the retrotranslocation machinery can be represented as a single entity and retrotranslocation as a two-step process. Again, this assumption allows us to use MichaelisMenten enzyme kinetics for ERAD, where
Rate constants used in the FoldEx model were based on experimental data when possible (see Figure 3 ). In the absence of experimental data, estimates typical for the processes involved were used. These parameters were inserted into the rate equations, which were then solved for the steady state to yield the synthesis and export rates necessary to calculate the relative export efficiency under the specified conditions. Although FoldEx includes basic parameters that can be systematically varied to scrutinize the model to determine their validity based on established experimental data and to reveal new features of ER function for protein export, we recognize that it could be further elaborated in many ways. The chaperoning cycle could encompass the more elaborate calnexin-calreticulin cycle for N-linked glycans (Helenius and Aebi, 2004) ; it could include the influence of distinct chaperones and cochaperones (Gonzalez et al., 2002) ; more accurate models of unimolecular protein misfolding and multimolecular aggregation (brought about, for example, by chaperone concentrations falling below a critical level) could be used (Rieger et al., 2006) ; the biological pathways could be represented as integrated systems with positive and negative regulation (Robinson and Lauffenburger, 1996) ; and multidomain protein engagement of the export machinery could be defined on the basis of the folding energetics of the relevant domain. These additional features would make the model more realistic, but they would also make it more complex. A virtue of FoldEx is its simplicity, especially if such a model can explain experimental data and make predictions where data are lacking. Importantly, this simplicity allows the effects of changes in model parameters to be clearly defined.
The first test of FoldEx was to discern whether integrating protein folding energetics and the biology of protein homeostasis could recapitulate the experimental data in Figure 2 . The dotted lines generated using FoldEx demonstrate that this model can reproduce the form of the experimental cellular export data for BPTI (Kowalski et al., 1998 ) and M-TTR (Sekijima et al., 2005) . That the export efficiencies of two different proteins in two different cell types, one a lower eukaryote (yeast) and the other a higher eukaryote (BHK cells), can be described using the same model reflects the evolutionary conservation of protein export regulation.
Export Efficiencies of Fast-Folding Proteins Depend on Thermodynamics
We will first examine the influence of folding thermodynamics in determining export efficiency using FoldEx. This is best accomplished by modeling a monomeric protein that folds much faster than it can be exported or retrotranslocated and does not misfold (k U/M = 0). Chaperones would be unnecessary for such proteins, so they are not considered here ([C] tot = 0), although chaperones can bind unfolded proteins, thus preventing them from folding and slowing the observed protein folding rate. Nevertheless, modeling with FoldEx demonstrates that neglecting chaperones in this case does not affect export efficiency; see Supplemental Experimental Procedures.
The steady-state export efficiency versus the folding equilibrium constant (K U/F ) for fast-folding proteins is plotted in Figure 4 . The folding equilibrium constant K U/F is the ratio of the folding and unfolding rate constants (e.g., K U/F = k U/F /k F/U ). The concentrations of export ([E] tot ) and retrotranslocation ([R] tot ) machineries were both set to 0.1 mM to balance their influence on export efficiency. The black curve shows that the model gives the result required by experimental observations: the dependence of export efficiency on thermodynamic stability is sigmoidal, reaching a maximum of 1. It is therefore possible for fastfolding proteins with substantially destabilizing mutations to be exported with essentially the same efficiency as more thermodynamically stable WT variants. For example, if a WT protein had K U/F = 10 4 , the black curve in Fig- ure 4A shows that it would have an export efficiency of 1.0. If a mutation decreased K U/F to 10 2 (a factor of 100), the export efficiency would still be nearly 1.0. The export efficiency of the mutant protein, in a given cell type, is dictated by its absolute stability, not by its stability relative to the WT protein, all else being equal. This effect has been observed experimentally in the export of M-TTR (Sekijima et al., 2005) , as shown in Figure 2A .
Export Efficiencies of Fast-Folding Proteins Depend on the Relative Activities of the Export and ERAD Pathways
The rate constants and concentrations used for the export and retrotranslocation machineries in the preceding section were the same. Thus, V max and K M for export and ERAD were the same (the export and ERAD pathways had the same activities). But what happens when the two pathways have different activities? The colored curves in Figure 4A show the dependence of the export efficiency on the folding equilibrium constant for a fastfolding protein when export is more active than ERAD (light blue and blue curves), or when ERAD is more active than export (orange and red curves). Export efficiencies increase as the activity of the export pathway increases (the export efficiency curve shifts to the left when [E] tot > [R] tot ), and decrease as the activity of the ERAD pathway increases (the export efficiency curve shifts to the right when [R] tot > [E] tot ). Thus, the model suggests that modest inhibition of ERAD could remedy excessive ERAD and loss of function that leads to numerous familial loss-of-function misfolding diseases, including Gaucher disease.
The dependence of export efficiency on folding energetics, ERAF, ERAD, and export activities can be best illustrated in terms of a minimal export threshold (MxT), defined as that equilibrium constant affording a certain export efficiency (here we choose 0.1). The MxT increases as [R] tot increases and decreases as [E] tot increases ( Figure 4B) , showing that the dependence of export efficiency on protein folding energetics can shift dramatically as the relative activities of the export and ERAD pathways are altered. It should be noted that similar effects could be obtained by altering the k cat or K M of the export and retrotranslocation machineries, for instance by allosteric regulation or by interaction with accessory proteins. Thus, the MxT is strongly influenced by the biology of ERAF, ERAD, and export pathways.
Export Efficiencies of Slow-Folding Proteins Are Sensitive to Protein Folding Kinetics
In the previous two sections, we assumed that protein folding was fast (equilibrium was reached before the export or ERAD machinery could be engaged). This likely will be true only for small monomeric proteins, because folding rates tend to decrease as the size of the protein increases (Li et al., 2004) . Proteins that fold with moderate or slow rates (relative to the rates of export and ERAD) are susceptible to ERAD during the time that they are in the unfolded conformational ensemble, which decreases their export efficiency, even if they are thermodynamically stable once folded. This effect is illustrated by Figure 5A , which consists of plots of export efficiency versus folding equilibrium constant for proteins with progressively slower folding reflected by increasing half-times for folding (t 1/2,F ). The half-time is defined as the time required for a unimolecular folding reaction to progress halfway to equilibrium: t 1/2,F = (ln 2)/(k U/F + k F/U ). Again, the activities of the export and ERAD machineries were set equal to each other to focus on the effect of folding kinetics. Figure 5A shows that, for a protein with a given folding equilibrium constant, the export efficiency decreases as t 1/2,F increases. This effect is small at first, but becomes substantial when the folding rate becomes comparable to the rate at which the export and retrotranslocation machinery operate. Given the rate constants in Figure 3 and [E] tot = [R] tot = 0.1 mM, this occurs when t 1/2,F $ 10 s. Thus, even very stable proteins may be degraded to a considerable extent if they fold slowly, an important issue for large, multidomain proteins such as CFTR and other transmembrane proteins that can require up to 10 min for synthesis and folding (Riordan, 2005) . Figure 5A shows that a very stable protein with a folding equilibrium constant (K U/F ) of 10 4 would have an export efficiency of only 0.4 when its t 1/2 of folding is 10 s. Figure 5B further illustrates the effect of folding kinetics on the MxT; K U/F is plotted on the horizontal axis and the t 1/2,F of folding is plotted on the vertical axis, whereas the curved black line represents the MxT. The K U/F , t 1/2,F combinations that fall in the red region of the plot are below the MxT, and those in the light blue region are above the MxT. Figure 5B shows that the MxT is largely independent of the folding rate when folding is much faster than ERAD and export (a t 1/2,F < 1 s for this case), and that the MxT cannot be reached no matter how stable a protein is when folding is much slower than ERAD and export (a t 1/2,F > 70 s in this case), hence FoldEx predicts that pharmacologic chaperones (native state stabilizing small molecules) would be ineffective in this case, whereas a decrease in ERAD activity could provide these proteins an opportunity to fold. In contrast, the MxT is strongly dependent on both stability and folding rate at intermediate folding rates (1 s < t 1/2,F < 70 s). This indicates that both substantially contribute to export efficiency at a given balance of ERAF, ERAD, and export machineries and that proteins with intermediate folding rates that arise from mutation are more ''correctable.'' Figure 4 demonstrates that the export efficiencies of fastfolding proteins such as TTR depend on the relative activities of the export and ERAD pathways and that the effects of the two pathways on export are symmetrical. This means that increasing the concentrations of the export or retrotranslocation machineries shifts the export efficiency versus folding equilibrium constant curve in opposite directions, but to equal degrees. This symmetry no longer exists for slow-folding proteins such as CFTR. Figure 5C Figure 5C ).
Slow-Folding and Fast-Folding Proteins Differ in Their Responses to Export and Retrotranslocation Activity Changes
This asymmetry is evident in the MxT representation of the data ( Figure 5D ). As the [E] tot decreases relative to a fixed [R] tot ( Figure 5D , panels 1-3), the MxT will support export of only increasingly stable and fast-folding proteins. The MxT retreats to smaller and smaller portions of the upper right-hand corners of the plots when [R] tot R [E] tot ( Figure 5D , panels 3-5), indicating that proteins must fold faster and be more stable to be exported with minimal efficiency when [R] tot > [E] tot . Hence, increasing relevant export activity and/or decreasing ERAD activity is predicted to restore export and function in cases where excessive ERAD leads to loss-of-function diseases. The asymmetric effects of the export and ERAD activities on the export efficiency of slow-folding proteins is caused by a change in the rate-limiting step in the export pathway as [E] tot increases. The rate at which the export machinery operates is proportional to [E] tot (as V max is proportional to [E] tot ). When folding is fast, it is unlikely that [E] tot can ever become large enough for export to be faster than folding. Thus, export is always the rate-limiting step for fast-folding proteins. However, when folding is not fast, export can become faster than folding when [E] tot (and therefore the V max for export) is sufficiently large. Folding then becomes the rate-limiting step in the export pathway, and thus the effect of increasing [E] tot on the export efficiency diminishes. ERAD is different from export in that there are no steps between the unfolded conformational ensemble and its recognition by the retrotranslocation machinery. ERAD is always rate limited by the rate at which the retrotranslocation machinery operates, and increasing the concentration of the [R] tot consequently has a strong effect on export efficiency for both fastand slow-folding proteins; thus, modest ERAD inhibition could have a substantial impact in protein homeostasis diseases.
Chaperones Improve Export Efficiency for Proteins Prone to Misfolding by Altering the MxT
We have assumed that misfolded proteins cannot revert to the unfolded state without the assistance of the chaperones found in the ERAF pathway. In the absence of the ERAF pathway, the only option for a misfolded protein is ERAD. Misfolding would therefore irremediably decrease export efficiency. The ERAF pathway, however, can compete with ERAD to recover misfolded proteins. Chaperones can interact with misfolded/misassembled proteins and convert them to unfolded proteins (Bukau et al., 2006; Young et al., 2004) , giving them another chance to fold and be exported (Figure 3) . This increases the export efficiency of misfolding-prone proteins Wang et al., 2006) .
The effect of protein misfolding on export efficiency is illustrated by Figure 6A , which consists of plots of export efficiency versus folding equilibrium constant (stability) for proteins with a series of increasing misfolding rates. The misfolding rate is represented by the half-time for misfolding (t 1/2,M = (ln 2)/k U/M ). Here we find that the export efficiency decreases as protein misfolding becomes faster (i.e., as t 1/2,M decreases), even for very stable proteins. Thus, when protein misfolding is significant, the MxT depends not only on the thermodynamics and kinetics of folding but also on the kinetics of misfolding. We can therefore plot the MxT for misfolding-prone proteins in the absence of chaperone ([C] tot = 0) as a surface in Figure 6B . This plot shows that the MxT constricts for a given value of stability (x axis) as the misfolding rate (z axis) increases and the folding rate (y axis) decreases. FoldEx demonstrates that proteins that misfold quickly are unlikely to be exported efficiently, unless they fold even faster and are very stable once folded.
Chaperones in the ERAF pathway afford misfolded proteins another opportunity to fold. We refer to this adaptable environment as the modular ''chaperome'' (Wang et al., 2006) , where the word ''modular'' reflects the capacity of various chaperone activities to be tunable through their steady-state concentrations and through the influence of cochaperones, other regulatory molecules, and posttranslational modifications. Thus, increasing the activity of the chaperome (in this case [C] tot ) increases the activity of the ERAF pathway, making the chaperome environment more pro-folding and increasing export efficiency ( Figure 6C ; t 1/2,F = t 1/2,M = 1 s). At the highest chaperome concentration, if biologically feasible, FoldEx predicts that misfolding could be eliminated. Figure 6D shows that the MxT encloses a larger volume in the plot as [C] tot increases (from 0.1 mM in panel 1 to 10 mM in panel 3). It also becomes less sensitive to the misfolding rate: at [C] tot = 10 mM, the MxT is independent of the misfolding half-time, until t 1/2,M < 1 s. The effect of ERAF on protein export in the model is consistent with many reports that chaperone overexpression increases the export of proteins from cells (Borth et al., 2005; Xu et al., 2005) . Thus, the modular chaperome pool plays a central role in adjusting the MxT to augment export efficiency for both WT and misfolding-prone proteins. FoldEx suggests that protein homeostasis modifiers that both enhance ERAF and inhibit ERAD could restore folding and export to proteins with substantially compromised energetics.
DISCUSSION
We utilize a Michaelis-Menten treatment of the protein homeostasis pathways (ERAD, ERAF, export) to model endoplasmic reticulum function in protein export, an approach that integrates protein energetics into the decisions made by the biological components of the ER. This simplified model captures many features of the ER that have not been comprehensively described previously, one being that the adjustable biological capacities of the folding, degradation, and export pathways dictate, in concert with folding energetics, an adaptable standard for protein export. FoldEx also makes numerous unanticipated testable predictions regarding the biology of the ER that have a fundamental impact on our understanding of protein homeostasis and cellular diversity in health and disease.
An Adaptable Standard for Protein Export
There is a consensus that mutated proteins are degraded by ERAD if they are less stable than WT, or exported if they are equally or more stable than WT (Helenius and Aebi, 2004 ). The FoldEx model moves beyond this ''quality control'' (QC) concept, revealing that export efficiency is influenced by folding and misfolding energetics, as well as by the adjustable biological activities of the ERAF, ERAD, and export pathways specific to each cell type. Thus, there is no one QC standard for export. A variable standard is a key feature of ER function that is more appropriately thought of as protein homeostasis control than QC, given the need to adapt protein cargo folding to normal cellular function. Thus, FoldEx explains why different cell types handle the same WT or mutant protein differently, dependent on their unique biology and the expressed proteome in the cell of interest.
Predictions from the FoldEx Model for Normal Cellular Physiology
FoldEx rationalizes the observation that with some proteins, thermodynamic stability correlates with export efficiency (Kowalski et al., 1998) , whereas in other cases, both kinetics and thermodynamics strongly influence the concentration of the folded state that can engage the export machinery (Sekijima et al., 2005) . The model predicts that the dependence of export efficiency on energetics will be cell type specific. Moreover, two populations of the same cell type or the same cell in different environments could have very different export efficiencies, dependent on chaperone levels that could be upregulated by the unfolded protein response (Ron and Walter, 2007) in only one population or biological state. FoldEx rationalizes why large slow-folding membrane proteins have (A) Plots of the export efficiency versus stability for proteins with a moderate folding rate (t 1/2,F = 1 s) and variable misfolding rates (t 1/2,M ) when ERAF is unavailable ([C] tot = 0). (B) Plot of MxT as a function of protein stability (K U/F ), folding kinetics (t 1/2,F ), and misfolding kinetics (t 1/2,M ). The values of K U/F , t 1/2,F , and t 1/2,M on the blue surface give an export efficiency of 0.1, the MxT. (C) Plots of the export efficiency versus stability for a protein that misfolds with t 1/2,F = t 1/2,M = 1 s at varying levels of ERAF activity (expressed in terms of the chaperone concentration, [C] tot , 0-10 mM). (D) As in (B), except that [C] tot has been set to 0.1, 1, and 10 mM in panels 1, 2, and 3, respectively.
poor ER export efficiencies: because they fold slowly, high concentrations of the U and M states can build up that engage the ERAD pathway, such as is observed in cystic fibrosis (Loo and Clarke, 2007) . This also provides a framework to understand why large multimembranespanning proteins are unstable in suboptimal folding environments such as heterologous expression systems. FoldEx makes a number of predictions for protein homeostasis control that could be tested by proteomic and transcriptional analysis of highly specialized secretory cells. For example, we would expect that hepatocytes or highly specialized plasma B cells would have elevated ERAF/ export components to maximize protein export, as is observed (Shimizu and Hendershot, 2007) .
The FoldEx model emphasizes that a subset of proteins will be in competition for the basic ERAD, ERAF, and export machineries, and hence the export efficiency of a particular cargo protein will depend on the proteome being expressed at that time and the activity of the ERAD, ERAF, and export pathways. For example, FoldEx would predict that if two proteins of dissimilar stability were coexpressed, the less stable protein would outcompete the more stable protein for the ERAD machinery, resulting in higher export efficiency for the more stable protein. This could explain why coexpressing bovine pancreatic trypsin inhibitor (BPTI) and scFv D1.3 in yeast results in increased export of BPTI and, notably, decreased export of scFv D1.3 (Rakestraw and Wittrup, 2006) . Moreover, a proteome with numerous destabilizing polymorphisms will require more biological folding assistance and render a given destabilized protein more prone to ERAD than would a more stable proteome. Because of competition for both the ERAF and ERAD machinery, proteins with a propensity to aggregate (e.g., some variants of a 1 -antitrypsin; Perlmutter, 2006) are more likely to do so in the presence of a soluble misfolded protein cargo pool. This has been observed in the cytosol for Huntington Poly Q aggregation in the presence of misfolding-prone temperature-sensitive mutant proteins that titrate cytosolic chaperones (Gidalevitz et al., 2006) . Finally, the FoldEx model suggests that many other factors including the ER redox state and ER Ca 2+ homeostasis will have a high impact on protein homeostasis control given the requirement for PDI-like activities and numerous Ca 2+ binding chaperones, respectively.
Predictions from the FoldEx Model for Disease Intervention Protein-misfolding diseases involving the secreted proteome can be caused by ER export being either too permissive, resulting in export of aggregation-prone proteins leading to proteotoxicity, or too restrictive, resulting in loss-of-function disorders due to overzealous degradation of proteins that have sufficient function to support physiology. The FoldEx model demonstrates that what is a benign mutation in one cell type may be a disease-causing mutation in another, reflecting physiologic differences, as observed in Gaucher patients, wherein only a subset of the genetically identical monocyte/macrophage population exhibits glucocerebrosidase enzyme deficiency sufficient to cause glucosylceramide lysosomal storage. A similar situation is observed in cystic fibrosis patients, where identical siblings with the common DF508 mutation in CFTR have different clinical courses. These and related observations demonstrate that there is a very fine line between physiology and pathology, as predicted by FoldEx. Defining these differences is likely to yield critical insight into disease.
The FoldEx model enables the balance between ERAD, ERAF, misfolding kinetics, and export activities to be varied to test therapeutic concepts for protein-misfolding disease intervention. FoldEx predicts that no single strategy can succeed for all loss-of-function or all gain-oftoxicity protein-misfolding diseases, as is now evident because some mutations create kinetic challenges whereas others largely influence thermodynamic stability. FoldEx makes the important prediction that a chemical or biological approach that simultaneously enhances ERAF and partially inhibits ERAD should be a highly effective therapeutic strategy for loss-of-function diseases, especially for the problematic mutations that lead to slow folding and/or rapid misfolding such as the DF508 CFTR and L444P glucocerebrosidase mutations associated with cystic fibrosis and neuropathic Gaucher disease, respectively. Moreover, our model suggests that enhancing folding capacity utilizing a pharmacologic chaperone (Aridor, 2007) should exhibit synergy with the aforementioned approach, in which protein homeostasis is modulated, because ERAF activators hasten folding and inhibit misfolding by operating on conformational ensembles preceding the folded state, whereas pharmacologic chaperones stabilize the folded state. Although we have emphasized the role of mutations in misfolding diseases, type II diabetes is caused by excessive demand for the production of WT insulin that cannot be met. FoldEx predicts that using a chemical or biological approach to balance the ERAF and export pathways selective for insulin and amylin export would be an ideal strategy to ameliorate pancreatic b cell death in type II diabetes (Ozcan et al., 2006) . Additional FoldEx predictions for therapeutic strategies can be visualized graphically (Figure 7 ) using the minimal export threshold concept. The middle panel depicts two mutations that fall outside the exportable pool defined by the MxT, depicted by the transparent blue surface; one mutation (m1) is outside the MxT because it is thermodynamically destabilized and the second mutation (m2) is outside the MxT because it has a fast misfolding rate. The WT protein is inside the MxT, depicted by encasement within the transparent blue surface. FoldEx demonstrates that m1 can be brought inside the MxT by pharmacologic chaperone-induced stabilization (Figure 7, top panel) . In contrast, the misfolding rate of m2 is too fast for pharmacologic chaperone binding to bring it inside the MxT. However, increasing the activity of the ERAF machinery expands the MxT to the point that it places m2 within the MxT, restoring function (Figure 7 , lower panel). The other mutant, m1, cannot be rescued in this way because it does not populate the misfolded state enough for ERAF-mediated recovery to substantially increase its export efficiency. The validity of this strategy was recently demonstrated: decreasing the levels of the Hsp90 cochaperone Aha1 increased the level of CFTR function on the surface of a patient-derived cell line (Wang et al., 2006) . FoldEx predicts that an even larger increase in CFTR activity would be observed by also partially inhibiting ERAD.
Alternatively, gain-of-toxic function diseases (e.g., systemic amyloidoses) resulting from the export of destabilized proteins can be ameliorated by lowering the concentration of the exported protein. FoldEx predicts that this could be achieved by enhancing ERAD of misfolding-prone proteins. For example, overexpressing ERAD components such as Derlin-2 or -3 increases degradation of misfolding-prone glycoproteins (Oda et al., 2006) . Similarly, overexpressing EDEM in mammalian cells increases degradation of a 1 -antitrypsin (Hosokawa et al., 2001; Oda et al., 2003) . These results demonstrate that the ERAD machinery is a potential target for the treatment of amyloid diseases.
Conclusion
A simplified Michaelis-Menten treatment of the protein homeostasis network and a formal analysis of how the network of competing pathways evaluates protein folding kinetics and thermodynamics provide a framework for understanding the exocytic pathway for protein homeostasis control. FoldEx shows how this understanding moves beyond the concept of quality control by rationalizing an adaptable standard for protein export. FoldEx also makes predictions about protein folding and trafficking that can be tested experimentally, providing a rigorous framework to develop new therapeutic strategies for loss-and gainof-function misfolding diseases.
EXPERIMENTAL PROCEDURES Calculation of Steady-State Export Efficiencies
The steady-state export efficiency is the steady-state rate of protein export divided by the steady-state rate of protein synthesis. The former quantity is equal to the steady-state rate at which the export machinery turns over, or k EF/E [EF] ss (the subscript ss refers to steady state). Similarly, the latter quantity is equal to the steady-state rate at which protein is released from the ribosome in both chaperone-bound and -unbound forms, or k TU/T+U [TU] ss + k TUC1/T+C1U [TUC 1 ] ss . To determine the steady-state concentrations of the species of interest, the rate and mass balance equations of the FoldEx model must be solved at steady state. The rate equations are Center panel: three hypothetical proteins placed relative to the MxT (represented by the transparent surface) according to their stability, folding rate, and misfolding rate. The wild-type (WT) protein is represented by a blue point, and the two mutants (m1 and m2) are represented by red points. The first mutant (m1) is destabilized relative to the wt, whereas the second (m2) misfolds much faster than wt. Top panel: pharmacologic chaperoning can bring m1 but not m2 within the MxT, enabling enhanced secretion of m1. Bottom panel: increasing protein homeostasis capacity by increasing ERAF activity expands the volume of the MxT, bringing m2 but not m1 within it, enabling enhanced secretion of m2.
d½T dt = k TU/T + U ½TU + k TUC1/T + C1U ½TUC 1 À k T/TU ½T (4) d½TU dt = k T/TU ½T À ðk TU/T + U + k TU + C1/TUC1 ½C 1 Þ½TU
d½TUC 1 dt = k TU + C1/TUC1 ½TU½C 1 À k TUC1/T + C1U ½TUC 1 (6) d½C 1 dt = k C2U/C1 + U ½C 2 U À ðk TU + C1/TUC1 ½TU + k C1 + U/C1U ½U + k C1 + M/C1U ½MÞ½C 1 (7) 
Four mass balance equations can be written for this system, one for each of the classes of species that has a constant total concentration: the translocon (including T, TU, and TUC 1 ), the chaperone (including C 1 , TUC 1 , C 1 U, and C 2 U), the export machinery (including E and EF), and the retrotranslocation machinery (including R, RU, and RM):
½C tot = ½C 1 + ½C 1 U + ½C 2 U + ½TUC 1 (16)
½R tot = ½R + ½RU + ½RM:
The right-hand sides of Equations 1-14 equal 0 at steady state, allowing Equations 1-14 to be used to obtain expressions for [U] 
